Clinical Trials on Lymphoid Hematological Malignancies in Brazil

Total 469 results

AstraZeneca

Completed

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) (HUDSON GI)

Eosinophilic Gastritis | Eosinophilic Gastroenteritis

Italy, Spain, United States, Vietnam, Japan, Netherlands, Ukraine, Poland, Brazil
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Australia, Brazil, Spain, Italy, Canada, Germany, Chile, Mexico, France, Argentina, Croatia, Russian Federation, Slovakia, Turkey, Poland, Czechia, New Zealand, Portugal, Greece
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine
Sanofi

Active, not recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia, Czechia, Brazil, Japan, Greece, Portugal
Viracta Therapeutics, Inc.

Recruiting

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

EBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOS

United States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Chronic Myeloid Leukemia

United States, Spain, Australia, Canada, Hong Kong, Singapore, United Kingdom, Germany, Netherlands, Chile, India, South Africa, Sweden, Peru, Argentina, Italy, Austria, Colombia, Brazil, China, Finland, Hungary, Korea, Republic of, M... and more
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Pfizer

Active, not recruiting

Resolution of Sickle Cell Leg Ulcers With Voxelotor (RESOLVE)

Sickle Cell Disease | Leg Ulcers

Brazil, Nigeria, Kenya
Poitiers University Hospital
University Medical Center Groningen; Imperial College London; University of Liege and other collaborators

Recruiting

International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)

Chronic Myeloid Leukemia

Denmark, China, Germany, Australia, Belgium, Brazil, Chile, Croatia, Czechia, France, Greece, Japan, Lebanon, Poland, Spain, Turkey, Austria, Belarus, Netherlands, Slovakia
Viracta Therapeutics, Inc.

Completed

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Lymphoproliferative Disorders | Epstein-Barr Virus Associated Lymphoma

United States, Brazil
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Russian Federation, Czech Republic, Australia, United Kingdom, Italy, Brazil, Israel, Poland, Ukraine, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Pure Red-cell Aplasia

United Kingdom, Sweden, South Africa, Brazil, Norway, France, Thailand
AbbVie

Completed

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (METER)

Myelofibrosis

Argentina, Australia, Brazil, Canada, Colombia, Greece, Italy, Mexico, Poland, Portugal, Romania, Taiwan, Turkey, United States
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Spain, Sweden, Turkey, Korea, Republic of
GlaxoSmithKline

Completed

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Hypereosinophilic Syndrome

United States, Poland, Spain, France, Belgium, Germany, Argentina, Russian Federation, Mexico, Italy, Brazil, United Kingdom, Romania
Pfizer
Pfizer

Available

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Sickle Cell Disease

United States, Brazil
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

Hemophilia A | Children | Prophylaxis of Bleeding | Treatment of Bleeding

Canada, United States, Brazil, Italy, Turkey, Argentina, Norway
Novartis Pharmaceuticals

Recruiting

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Sickle Cell Disease

United States, Belgium, Spain, Lebanon, Brazil, Italy, Oman, Turkey, Germany, Colombia, France
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
GlaxoSmithKline

Completed

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Hypereosinophilic Syndrome

United States, Poland, Spain, France, Belgium, Germany, Argentina, Russian Federation, Mexico, Italy, Brazil, United Kingdom, Romania
Novartis Pharmaceuticals

Completed

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

India, United Kingdom, Netherlands, Canada, Germany, Greece, Italy, Poland, Russian Federation, Spain, Taiwan, Thailand, United States, Brazil, Bulgaria, Mexico, Romania, Ukraine
Hoffmann-La Roche

Completed

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Italy, Sweden, Belgium, Brazil, Canada, Germany, Ireland, Korea, Republic of, Spain, Russian Federation, France, Finland, Israel, Estonia, Romania, Egypt, Thailand, Switzerland, Bosnia and Herzegovina, Slovakia, Turkey, Lithuania, P... and more
Pfizer

Completed

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Febrile Neutropenia

United States, Brazil, Chile, Peru, Argentina, Pakistan, Venezuela, Colombia, Finland, Mexico
Biogen

Terminated

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)

Chronic Lymphocytic Leukemia

United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Lithuania, Poland, Romania, Australia, Argentina, Austria, Canada, France, Israel, New Zealand, Portugal, Slovakia, Greece, Germany, India, Bel...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes (PROMYS)

Myelodysplastic Syndromes | Adult

Belgium, United States, Austria, United Kingdom, Italy, Taiwan, Brazil, China, Croatia, Czechia, France, Germany
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
ApoPharma

Terminated

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)

Iron Overload | Sickle Cell Disease | Other Anemias

United States, Turkey, United Kingdom, Egypt, Saudi Arabia, Brazil, Canada, Tunisia
Novartis Pharmaceuticals

Terminated

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1)

Leukaemia, Lymphocytic, Chronic

Spain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Pfizer

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

Hemophilia A

Spain, Taiwan, Australia, United States, Japan, France, Turkey, Germany, Korea, Republic of, United Kingdom, Saudi Arabia, Canada, Greece, Sweden, Brazil, Italy
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Celgene

Completed

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (ORIGIN)

B-Cell Chronic Lymphocytic Leukemia

United States, Spain, Australia, Belgium, Italy, Serbia, Poland, Israel, New Zealand, Portugal, Brazil, France, Bulgaria, Croatia, Czechia, Hungary, Russian Federation, Netherlands, Romania, Denmark, United Kingdom, Austria, Canada, South... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) (CROSSWALK-c)

Sickle Cell Disease

Spain, United States, Brazil, United Kingdom, Italy, Turkey, Kenya, Netherlands, France, South Africa, Lebanon
AstraZeneca

Active, not recruiting

Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients (iOUTRUN)

Severe Asthma

United Arab Emirates, Brazil, Qatar, Saudi Arabia, Colombia, Dominican Republic, India, Kuwait
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Italy, Thailand, Romania, Croatia, Brazil, Arge... and more
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
Hoffmann-La Roche

Completed

(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Anemia

Italy, Spain, Mexico, Hungary, Singapore, Greece, United Kingdom, Austria, Thailand, Germany, Poland, Russian Federation, Denmark, Brazil, Sweden, Czech Republic, Finland
AstraZeneca
Iqvia Pty Ltd

Terminated

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease (HESTIA3)

Sickle Cell Disease

Italy, Spain, United Kingdom, Belgium, United States, India, South Africa, Brazil, Turkey, Egypt, Ghana, Greece, Kenya, Lebanon, Tanzania, Uganda
GlaxoSmithKline

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY)

Hypereosinophilic Syndrome

United States, Italy, Japan, Spain, Argentina, Belgium, China, Korea, Republic of, Czechia, Germany, Israel, Denmark, Poland, Brazil, Greece, Turkey, Mexico, Australia, Hong Kong, Romania, United Kingdom
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain

Clinical Trials on Lymphoid Hematological Malignancies in Brazil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations